Petmed Express (PETS) reported $179M in revenue for fiscal 2025, −21.1% year on year. That ranks #2705 by revenue among 2853 SEC filers and #295 in Healthcare. It posted a net loss of −$57.3M for the same year. Revenue has declined 2.7% a year on average since 2015 ($235M then). The fiscal 2025 balance sheet shows $88.0M in total assets and $26.9M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $179M | −21.1% | FY20252026-03-31 |
| Gross profitGrossProfit | $50.2M | −27.4% | FY20252026-03-31 |
| Operating incomeOperatingIncomeLoss | −$58.7M | −$57.1M | FY20252026-03-31 |
| Net incomeNetIncomeLoss | −$57.3M | −$51.0M | FY20252026-03-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$28.4M | −$33.1M | FY20252026-03-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $4.6M | −9.7% | FY20252026-03-31 |
| Total assetsAssets | $88.0M | −39.2% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $32.8M | −65.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $26.9M | −46.3% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q2 20262026-06-30 | $41.0M | −$6.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Petmed Express Inc
- Ticker
- PETS
- Exchange
- Nasdaq
- SIC classification
- Retail-Drug Stores and Proprietary Stores (5912)
- Fiscal year end
- 03-31
- CIK
- 0001040130
Filings
- 10-QAug 13, 2026Open filing →
- 10-KJun 2, 2026Open filing →
- 10-QFeb 5, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Stoke TherapeuticsSTOK | $184M | −$6.9M |
| Glass House BrandsGLAS | $182M | −$29.7M |
| KamadaKMDA | $180M | $20.2M |
| Petmed ExpressPETS | $179M | −$57.3M |
| CryoportCYRX | $176M | $78.3M |
| HeartflowHTFL | $176M | −$117M |
| Phathom PharmaceuticalsPHAT | $175M | −$221,250 |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Petmed Express — Key figures |url=https://companiesranked.com/en/company/petmed-express |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Petmed Express — Key figures. CompaniesRanked. https://companiesranked.com/en/company/petmed-expressBibTeX
@misc{companiesranked-en-company-petmed-express-2026,
author = {{CompaniesRanked}},
title = {{Petmed Express — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/petmed-express}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001040130-26-000019 · June 2, 2026
{{cite web |title=Petmed Express — Key figures — 10-K (0001040130-26-000019) |url=https://www.sec.gov/Archives/edgar/data/1040130/000104013026000019/pets-20260331.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-06-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.